학술논문
High power short duration versus low power long duration ablation in patients with atrial fibrillation: A meta‐analysis of randomized trials.
Document Type
Article
Author
Parlavecchio, Antonio; Vetta, Giampaolo; Coluccia, Giovanni; Pistelli, Lorenzo; Caminiti, Rodolfo; Ajello, Manuela; Magnocavallo, Michele; Dattilo, Giuseppe; Foti, Rosario; Carerj, Scipione; Crea, Pasquale; Chierchia, Gian Battista; de Asmundis, Carlo; Della Rocca, Domenico Giovanni; Palmisano, Pietro
Source
Subject
*LEFT heart ventricle
*RELATIVE medical risk
*META-analysis
*MEDICAL information storage & retrieval systems
*VENTRICULAR ejection fraction
*CONFIDENCE intervals
*STROKE
*TRANSIENT ischemic attack
*RADIO frequency therapy
*SYSTEMATIC reviews
*CATHETER ablation
*ATRIAL fibrillation
*SURGICAL complications
*TREATMENT duration
*DISEASE relapse
*RISK assessment
*TREATMENT effectiveness
*CARDIAC tamponade
*HEART atrium
*TACHYCARDIA
*DESCRIPTIVE statistics
*PULMONARY veins
*MEDLINE
*STATISTICAL models
*DATA analysis software
*ESOPHAGUS diseases
*DISEASE risk factors
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
Language
ISSN
0147-8389
Abstract
Background: High‐power‐short‐duration (HPSD) radiofrequency (RF) ablation is a viable alternative to low‐power‐long‐duration (LPLD) RF for pulmonary vein isolation (PVI). Nevertheless, trials showed conflicting results regarding atrial fibrillation (AF) recurrences and few data concerning complications. Therefore, we conducted a meta‐analysis of randomized trials comparing HPSD versus LPLD. Methods: We systematically searched the electronic databases for studies published from inception to March 31, 2023 focusing on HPSD versus LPLD. The study endpoints were AF recurrence, procedural times and overall complications. Results: Five studies enrolling 424 patients met the inclusion criteria (mean age 61.1 years; 54.3% paroxysmal AF; mean LVEF 58.2%). Compared to LPLD, HPSD showed a significantly lower AF recurrence rate [16.3% vs. 30,1%; RR: 0.54 (95% CI: 0.38–0.79); p = 0.001] at a mean 10.9 months follow‐up. Moreover, HPSD led to a significant reduction in total procedural time [MD: −26.25 min (95%CI: −42.89 to −9.61); p = 0.002], PVI time [MD: −26.44 min (95%CI: −38.32 to −14.55); p < 0.0001], RF application time [MD: −8.69 min (95%CI: −11.37 to −6.01); p < 0.00001] and RF lesion number [MD: −7.60 (95%CI: −10.15 to −5.05); p < 0.00001]. No difference was found in either right [80.4% vs. 78.2%; RR: 1.04 (95% CI: 0.81–1.32); p = 0.77] or left [92.3% vs. 90.2%; RR: 1.02 (95% CI: 0.94–1.11); p = 0.58] first‐pass isolation and overall complications [6% vs. 3.7%; RR: 1.45 (95%CI: 0.53–3.99); p = 0.47] between groups. Conclusion: In our metanalysis of randomized trials, HPSD ablation appeared to be associated to a significantly improved freedom from AF and shorter procedures, without increasing the risk of complications. [ABSTRACT FROM AUTHOR]